5 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting. 11 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Recruiting 5, Active not recruiting 1, Completed 1, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Recruiting 2 |
Follow Borderline Resectable Pancreatic Adenocarcinoma: new trials by email Literature Review of Borderline Resectable Pancreatic Adenocarcinoma trials Research Report on Borderline Resectable Pancreatic Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation HRS-4642+AG+Nimotuzumab - Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Zhejiang University | 40 | 2026-02-15 | 2026-02-13 |
| IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer IBI343 - Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Not yet recruiting | Zhejiang University | 40 | 2026-02-01 | 2026-02-17 |
| Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) Pembrolizumab, Folfirinox, SABR - Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Amsterdam UMC, location VUmc | 66 | 2024-09-23 | 2026-02-13 |
| Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Nab paclitaxel, Gemcitabine, Radiological Assessments - Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Wake Forest University Health Sciences | 64 | 2023-08-01 | 2026-09-28 |
| New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study Cisplatin, Fluorouracil, Gemcitabine - Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2023-04-18 | 2026-05-04 | |
| Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma mFOLFIRINOX or Gemcitabine nab-paclitaxel, Isotoxic High-Dose (iHD)-SBRT, Surgery - Pancreatic Neoplasm, Pancreatic Adenocarcinoma | Phase 2 | Recruiting | Erasme University Hospital | 256 | 2023-03-24 | 2023-05-23 |
| Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Biospecimen Collection, Computed Tomography, Core Biopsy - Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 141 | 2023-03-07 | 2026-11-09 |
| A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer mFOLFIRINOX, 5-Fluorouracil (5-FU), Oxaliplatin - Pancreatic Cancer, Resectable Pancreatic Cancer | Phase 2 | Terminated | Kimberly Perez, MD | 8 | 2023-01-06 | 2024-12-17 |
| Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer Durvalumab, Gemcitabine, Nab-paclitaxel - Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 13 | 2021-09-28 | 2026-10-07 |
| Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer Paclitaxel protein bound, Gemcitabine, Cisplatin - Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Completed | HonorHealth Research Institute | 19 | 2020-12-01 | 2026-07-21 |
| Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma Aglatimagene besadenovec, Chemoradiation, Stereotactic body radiation therapy - Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Unknown | Candel Therapeutics, Inc. | 54 | 2015-10-01 | 2024-01-08 |
Digestive System Diseases (4) · Digestive System Neoplasms (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Pancreatic Diseases (4)
Gemcitabine (4) · Taxes (4) · Fluorouracil (3) · Irinotecan (3) · Leucovorin (3) · Oxaliplatin (3) · Surgical Procedures, Operative (3) · 130-nm albumin-bound paclitaxel (2) · Albumin-Bound Paclitaxel (2) · Chemoradiotherapy (2) · Cisplatin (2) · dehydroftorafur (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Biopsy, Large-Core Needle (1) · Biopsy, Needle (1)
M.D. Anderson Cancer Center (2) · Zhejiang University (2) · Amsterdam UMC, location VUmc (1) · Candel Therapeutics, Inc. (1) · Erasme University Hospital (1) · HonorHealth Research Institute (1) · Jonsson Comprehensive Cancer Center (1) · Kimberly Perez, MD (1) · Wake Forest University Health Sciences (1)
United States (6) · China (2) · Belgium (1) · Mexico (1) · Netherlands (1)
Brandon G Smaglo (1) · Christelle Bouchart, MD (1) · Erkut Borazanci, MD (1) · Eugene J Koay (1) · Jean-Luc Van Laethem, MD (1) · Kimberly Perez, MD (1) · Ravi K Paluri, MD, MPH (1) · Zev A Wainberg (1)
2023 (1), P30CA012197 (1)